The drug, however, is no longer available to Kaufman or other Parkinson's patients in clinical trials.
Two months later, the company said that safety issues had been discovered and it abruptly ordered all patients taken off the drug.
The government said Switzerland should not lose its edge in pharmacology and bio-technology by banning stem cell research, which provides hopes for the treatment of various diseases, such as paralysis, heart attack, diabetes, Parkinson's disease and Alzheimer's.
Amgen concluded that the positive results in the earlier trials represented a placebo effect, something that is known to occur in Parkinson's trials.
